Transplantation in the hepatitis B patient and current therapies to prevent recurrence

Steven D Colquhoun, Steven H. Belle, Didier Samuel, Timothy L. Pruett, Lewis W. Teperman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hepatitis B is the sixth most common indication for liver transplantation in the United States, accounting for about 7% of all transplants among adults. Transplantation for hepatitis B is especially problematic because the virus is not eradicated and there is great potential for reinfection that can lead to graft failure or death. This risk is higher still in patients with active viral replication and chronic liver disease. Treatment with short-term hepatitis B immune globulin (HBIG) delays reinfection of the allograft, but only long-term treatment with HBIG has led to a decline in the reinfection rate. Combination therapy using HBIG with nucleoside analogues will likely become the standard of care to maintain stable serum titers of protective anti-HBs antibody and to prevent posttransplantation reinfection.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalSeminars in Liver Disease
Volume20
Issue number1 SUPPL.
StatePublished - Jul 12 2000
Externally publishedYes

Fingerprint

Hepatitis B
Transplantation
Recurrence
Immunoglobulins
Transplants
Therapeutics
Standard of Care
Nucleosides
Liver Transplantation
Allografts
Liver Diseases
Anti-Idiotypic Antibodies
Chronic Disease
Viruses
Serum

Keywords

  • Immunoprophylaxis
  • Liver transplantation
  • Reinfection
  • Risk factors
  • Treatment

ASJC Scopus subject areas

  • Hepatology

Cite this

Colquhoun, S. D., Belle, S. H., Samuel, D., Pruett, T. L., & Teperman, L. W. (2000). Transplantation in the hepatitis B patient and current therapies to prevent recurrence. Seminars in Liver Disease, 20(1 SUPPL.), 7-12.

Transplantation in the hepatitis B patient and current therapies to prevent recurrence. / Colquhoun, Steven D; Belle, Steven H.; Samuel, Didier; Pruett, Timothy L.; Teperman, Lewis W.

In: Seminars in Liver Disease, Vol. 20, No. 1 SUPPL., 12.07.2000, p. 7-12.

Research output: Contribution to journalArticle

Colquhoun, SD, Belle, SH, Samuel, D, Pruett, TL & Teperman, LW 2000, 'Transplantation in the hepatitis B patient and current therapies to prevent recurrence', Seminars in Liver Disease, vol. 20, no. 1 SUPPL., pp. 7-12.
Colquhoun, Steven D ; Belle, Steven H. ; Samuel, Didier ; Pruett, Timothy L. ; Teperman, Lewis W. / Transplantation in the hepatitis B patient and current therapies to prevent recurrence. In: Seminars in Liver Disease. 2000 ; Vol. 20, No. 1 SUPPL. pp. 7-12.
@article{2818a12972ed4d38875533363831d44d,
title = "Transplantation in the hepatitis B patient and current therapies to prevent recurrence",
abstract = "Hepatitis B is the sixth most common indication for liver transplantation in the United States, accounting for about 7{\%} of all transplants among adults. Transplantation for hepatitis B is especially problematic because the virus is not eradicated and there is great potential for reinfection that can lead to graft failure or death. This risk is higher still in patients with active viral replication and chronic liver disease. Treatment with short-term hepatitis B immune globulin (HBIG) delays reinfection of the allograft, but only long-term treatment with HBIG has led to a decline in the reinfection rate. Combination therapy using HBIG with nucleoside analogues will likely become the standard of care to maintain stable serum titers of protective anti-HBs antibody and to prevent posttransplantation reinfection.",
keywords = "Immunoprophylaxis, Liver transplantation, Reinfection, Risk factors, Treatment",
author = "Colquhoun, {Steven D} and Belle, {Steven H.} and Didier Samuel and Pruett, {Timothy L.} and Teperman, {Lewis W.}",
year = "2000",
month = "7",
day = "12",
language = "English (US)",
volume = "20",
pages = "7--12",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Transplantation in the hepatitis B patient and current therapies to prevent recurrence

AU - Colquhoun, Steven D

AU - Belle, Steven H.

AU - Samuel, Didier

AU - Pruett, Timothy L.

AU - Teperman, Lewis W.

PY - 2000/7/12

Y1 - 2000/7/12

N2 - Hepatitis B is the sixth most common indication for liver transplantation in the United States, accounting for about 7% of all transplants among adults. Transplantation for hepatitis B is especially problematic because the virus is not eradicated and there is great potential for reinfection that can lead to graft failure or death. This risk is higher still in patients with active viral replication and chronic liver disease. Treatment with short-term hepatitis B immune globulin (HBIG) delays reinfection of the allograft, but only long-term treatment with HBIG has led to a decline in the reinfection rate. Combination therapy using HBIG with nucleoside analogues will likely become the standard of care to maintain stable serum titers of protective anti-HBs antibody and to prevent posttransplantation reinfection.

AB - Hepatitis B is the sixth most common indication for liver transplantation in the United States, accounting for about 7% of all transplants among adults. Transplantation for hepatitis B is especially problematic because the virus is not eradicated and there is great potential for reinfection that can lead to graft failure or death. This risk is higher still in patients with active viral replication and chronic liver disease. Treatment with short-term hepatitis B immune globulin (HBIG) delays reinfection of the allograft, but only long-term treatment with HBIG has led to a decline in the reinfection rate. Combination therapy using HBIG with nucleoside analogues will likely become the standard of care to maintain stable serum titers of protective anti-HBs antibody and to prevent posttransplantation reinfection.

KW - Immunoprophylaxis

KW - Liver transplantation

KW - Reinfection

KW - Risk factors

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0033932504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932504&partnerID=8YFLogxK

M3 - Article

C2 - 10895438

AN - SCOPUS:0033932504

VL - 20

SP - 7

EP - 12

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1 SUPPL.

ER -